Mode of action
Belinostat belongs to a class of anti-cancer agents, HDACi,
which by enzymatic process (acetylation) works to normalize the
abnormal gene function pattern characteristic of cancer cells.
Belinostat is a strong member of the HDACi group as it:
- Has demonstrated anti-cancer activity against a variety of
- Is well-tolerated with minimal or no impact on bone marrow
- Can be administered both by infusion and orally